News Releases

Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.

Site search

2023

August 30, 2023

Taiho Pharmaceutical Announces the Launch of FGFR Inhibitor LYTGOBI_® Tablets 4mg in Japan
August 25, 2023

Taiho Pharmaceutical and Phost'in Therapeutics Announce an Option and License Agreement on the First-in-Class GnT-V Inhibitor PhOx430（PDF：315.8 KB）
August 07, 2023

REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations（PDF：361.4 KB）
August 03, 2023

FDA Approves LONSURF^®(trifluridine/tipiracil)in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)（PDF：418.4 KB）
August 01, 2023

European Commission Approves LONSURF^® (Trifluridine/tipiracil) in Combination With Bevacizumab
in 3rd Line Refractory Metastatic Colorectal Cancer (mCRC)
July 05, 2023

European Commission Grants Conditional Marketing Authorization for Taiho's LYTGOBI^®Tablets for the Treatment of Adults With Cholangiocarcinoma（PDF：380.2 KB）
July 03, 2023

Taiho Pharmaceutical to Provide Matching Funds to Select Crowdfunded Projects Addressing Issues in the Field of Oncology The Third "Taiho Smile Support"
June 26, 2023

Taiho Pharmaceutical Obtains Approval in Japan to Manufacture and Market FGFR Inhibitor LYTGOBI_® Tablets 4mg for Unresectable Biliary Tract Cancer Harboring FGFR2 Gene Fusions That Has Progressed After Chemotherapy
June 26, 2023

CHMP Issues Positive Opinion for Trifluridine/tipiracil (LONSURF^®) in Combination With Bevacizumab in 3rd Line Refractory Metastatic Colorectal Cancer (mCRC)
June 26, 2023

Taiho Pharmaceutical and Kyushu University Launch Joint Research for the Development of Novel Covalent Reactive Groups with a view to advance Covalent Drugs（PDF：279.5 KB）
May 18, 2023

Taiho Pharmaceutical Enters into a Clinical Trial Agreement with Arcus Biosciences and Gilead Sciences
April 27, 2023

CHMP ISSUES POSITIVE OPINION FOR FUTIBATINIB FOR THE TREATMENT OF ADULTS WITH CHOLANGIOCARCINOMA（PDF：384.1 KB）
April 19, 2023

U.S. Food and Drug Administration Accepts for Priority Review Supplemental New Drug Application for the Use of Trifluridine/Tipiracil (LONSURF®) in Combination With Bevacizumab for Refractory Metastatic Colorectal Cancer
Taiho（PDF：333.7 KB）
March 14, 2023

Taiho Pharmaceutical Announces Personnel Changes（PDF：178.6 KB）
March 07, 2023

Disinfect Your Mouth While Going about Your Day Taiho Pharmaceutical Offers PITAS Medical Troche Via Its Online Shop on March 7

News Releases

Select year from the Back Number